• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma

by | Mar 11, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Pharmacists Play an Essential Role in Bispecific Therapy for Multiple Myeloma

by | Mar 8, 2025 | Myeloma News

Source: Pharmacy Times articles Pharmacists also navigate the REMS program and monitor and manage adverse effect profiles associated with bispecifics. Read More

Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma

by | Mar 5, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection

by | Feb 28, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes

by | Feb 27, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Deep Responses in Smoldering Multiple Myeloma Linked to Improved Outcomes

by | Feb 26, 2025 | Myeloma News

Source: Pharmacy Times articles Risk stratification remains a challenge when selecting patients for treatment of smoldering multiple myeloma. Read More
« Older Entries
Next Entries »

Recent Content

  • Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
  • Prognostic and clinicopathological value of the controlling nutritional status score in patients with multiple myeloma: a meta-analysis
  • What Role Does MRD Play in Multiple Myeloma Treatment Decision Making?
  • Depression, anxiety prevalent among adults with lymphoma, multiple myeloma
  • Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis
  • Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma
  • Quadruplet Regimen Preferable to Triplets in Multiple Myeloma
  • Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis
  • Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review
  • Daratumumab regimen improves survival in transplant-ineligible multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT